JP2023549855A5 - - Google Patents

Info

Publication number
JP2023549855A5
JP2023549855A5 JP2023528658A JP2023528658A JP2023549855A5 JP 2023549855 A5 JP2023549855 A5 JP 2023549855A5 JP 2023528658 A JP2023528658 A JP 2023528658A JP 2023528658 A JP2023528658 A JP 2023528658A JP 2023549855 A5 JP2023549855 A5 JP 2023549855A5
Authority
JP
Japan
Prior art keywords
lipopeptide
acid
isomer
salt
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549855A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/059416 external-priority patent/WO2022108883A1/en
Publication of JP2023549855A publication Critical patent/JP2023549855A/ja
Publication of JP2023549855A5 publication Critical patent/JP2023549855A5/ja
Pending legal-status Critical Current

Links

JP2023528658A 2020-11-17 2021-11-15 呼吸器処置 Pending JP2023549855A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063114976P 2020-11-17 2020-11-17
US63/114,976 2020-11-17
US202163211972P 2021-06-17 2021-06-17
US63/211,972 2021-06-17
PCT/US2021/059416 WO2022108883A1 (en) 2020-11-17 2021-11-15 Respiratory treatments

Publications (2)

Publication Number Publication Date
JP2023549855A JP2023549855A (ja) 2023-11-29
JP2023549855A5 true JP2023549855A5 (https=) 2024-11-20

Family

ID=81709617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528658A Pending JP2023549855A (ja) 2020-11-17 2021-11-15 呼吸器処置

Country Status (9)

Country Link
US (1) US20240002436A1 (https=)
EP (1) EP4247165A4 (https=)
JP (1) JP2023549855A (https=)
KR (1) KR20230110295A (https=)
AU (1) AU2021383599A1 (https=)
CA (1) CA3199088A1 (https=)
MX (1) MX2023005663A (https=)
TW (1) TW202233647A (https=)
WO (1) WO2022108883A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025101524A1 (en) * 2023-11-06 2025-05-15 Hbc Immunology Inc. Lipopeptide compounds, and use in modulating eosinophilia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2546164B1 (fr) * 1983-05-16 1987-07-17 Centre Nat Rech Scient Nouveaux derives de peptides, leur preparation et leur application comme inhibiteurs de l'elastase
JPH0611754B2 (ja) * 1985-10-09 1994-02-16 サントリー株式会社 ペプチダ−ゼ阻害作用を有する新規化合物及びその製法並びに用途
EP0201743B1 (en) * 1985-04-16 1992-04-01 Suntory Limited Dipeptide derivatives of fatty acids, process for preparing them, pharmaceutical composition and use
AU2003250586B2 (en) * 2002-08-12 2010-09-23 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes
WO2009046220A2 (en) * 2007-10-02 2009-04-09 Mdrna, Inc. Lipopeptides for delivery of nucleic acids
KR101250812B1 (ko) * 2011-03-18 2013-04-04 미원상사주식회사 언데세노일 디펩타이드 유도체 및 이를 함유하는 피부미백용 화장료 조성물
US20140154257A1 (en) * 2012-06-07 2014-06-05 Luanne Robalo DeChristopher Materials and methods for diagnosing and treating asthma and dietary Fru-AGEs related disorders including auto-immune and other diseases found to be associated with elevated RAGE. The specification describes methods to identify and make dietary derived advanced glycation end-products, known as Fru-AGEs, Fru-AGE-haptens, and Fru-AGE immune complexes, and to make monoclonal and polyclonal antibodies to this plurality of bio-molecules for use in immunoassays and for use as therapeutic agents
US9371276B1 (en) * 2015-03-21 2016-06-21 Mohan Murali Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
WO2017068477A1 (en) * 2015-10-18 2017-04-27 Rao M Surya Compound, composition and uses thereof

Similar Documents

Publication Publication Date Title
ES2280596T3 (es) Uso combinado de un compuesto de glp-1 y un inhibidor de una aldosa reductasa.
Imran et al. Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review
US12161610B2 (en) Method of viral inhibition
CN103648491B (zh) 用于抑制流感病毒复制的方法和药物组合物
JP2020503269A5 (https=)
JP2020500864A5 (https=)
CN101969944B (zh) 脂肪性肝病的治疗用医药组合物
JP2020536121A5 (https=)
JP2023549855A5 (https=)
JP2021517144A (ja) Cd47遮断療法およびcd38抗体の組み合わせ
EP2604264B1 (en) Pharmaceutical composition for treating viral diseases
NO332773B1 (no) Anvendelse av epotilon B og farmasoytisk preparat inneholdende en slik forbindelse
JP2019516797A5 (https=)
US5559107A (en) Regulation of immune response
JP2023521665A5 (https=)
Filipin et al. DHEA and testosterone therapies in Trypanosoma cruzi-infected rats are associated with thymic changes
JP6509244B2 (ja) 水晶体硬化抑制剤
JP7830324B2 (ja) グルカゴン様ペプチド1を含む安定な液体製剤及びその使用
JP2023549855A (ja) 呼吸器処置
WO2007018278A1 (ja) 肝癌発生・進展抑制剤
JP2003171266A (ja) キシリトールを含有する解熱性調剤
US20260060981A1 (en) Combination of 5-amino-2,3-dihydro-1,4-phthalazinedione and a fumaric acid ester
US20210228515A1 (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating anti-n-methyl-d-aspartate receptor encephalitis
Tieu et al. N-Acetylcysteine (NAC) and its Immunomodulatory Properties: Part I. Therapeutic uses of NAC in humans and livestock
WO2022161376A1 (zh) 一种含有西洛他唑的组合物在脑血管病中的应用